Q1 'very much a building quarter' for VolitionRx with growing cash reserves

Cameron Reynolds, president and chief executive of VolitionRx Ltd (NYSEMKTS:VNRX), discusses with Proactive Investors their Q1 2018 earnings.

The company reported a slower first quarter cash burn rate while growing cash reserves.

For the period ended March 31, it increased its cash and equivalents to US$14.3mln, compared to US$10.1mln in the previous quarter.

This week Volition entered into a sales and distribution partnership with Active Motif that will pave the way for the sale of a range of research-use-only (RUO) kits based on its proprietary Nucleosomics technology.

Quick facts: VolitionRx

Price: $4.18

Market Cap: $171.76 m


VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash. ''Total cash in hand that gives...

on 9/5/19

2 min read